New drug before surgery shows promise against lung cancer
NCT ID NCT03433469
First seen Apr 04, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study tests whether giving the drug osimertinib before surgery can shrink tumors in people with early-stage EGFR-mutant non-small cell lung cancer. About 27 adults with stage I to IIIA disease will receive osimertinib, then have surgery. The main goal is to see how many patients have a major reduction in tumor cells after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIA NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, Davis
Davis, California, 95864, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.